Literature DB >> 18034790

Sibutramine-associated adverse effects: a practical guide for its safe use.

M Florentin1, E N Liberopoulos, M S Elisaf.   

Abstract

Obesity is a multifactorial chronic disorder which comprises a serious health problem nowadays. The effective management of obesity is difficult in contemporary societies where abundance of hypercaloric food and sedentary lifestyle is the rule. Apart from lifestyle interventions, which include diet, exercise and behavioural treatment, weight-loss medications can also be used for the management of obesity. Sibutramine, a selective monoamine reuptake inhibitor, is a drug with established efficacy in sustained weight reduction and an overall favourable safety profile. However, its action on the sympathetic nervous system has linked sibutramine to blood pressure and heart rate elevations. These potentially adverse effects as well as other sibutramine-associated side effects and their possible underlying mechanisms are reviewed in the present article. Compelling evidence from the majority of data in the literature shows that sibutramine can be effectively used in conjunction with caloric restriction and exercise in obese patients. Hypertension, if adequately treated and frequently monitored, is not an absolute contraindication for the prescription of sibutramine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18034790     DOI: 10.1111/j.1467-789X.2007.00425.x

Source DB:  PubMed          Journal:  Obes Rev        ISSN: 1467-7881            Impact factor:   9.213


  10 in total

1.  Effects of the increase in neuronal fatty acids availability on food intake and satiety in mice.

Authors:  Roberto Coccurello; Antonio Caprioli; Sara Bellantuono; Francesca R D'Amato; Roberto Conti; Fabio Giannessi; Franco Borsini; Anna Moles
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

2.  Use of a pharmaceutically adulterated dietary supplement, Pai You Guo, among Brazilian-born women in the United States.

Authors:  Pieter A Cohen; Carly Benner; Danny McCormick
Journal:  J Gen Intern Med       Date:  2011-08-16       Impact factor: 5.128

3.  Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial.

Authors:  Ivan Ivanovich Dedov; Galina Afanasievna Melnichenko; Ekaterina Anatolievna Troshina; Natalya Valentinovna Mazurina; Marina Olegovna Galieva
Journal:  Obes Facts       Date:  2018-08-09       Impact factor: 3.942

4.  Sibutramine-induced mania as the first manifestation of bipolar disorder.

Authors:  Napoleon Waszkiewicz; Beata Zalewska-Szajda; Sławomir Dariusz Szajda; Katarzyna Simonienko; Anna Zalewska; Agata Szulc; Jerzy Robert Ładny; Krzysztof Zwierz
Journal:  BMC Psychiatry       Date:  2012-05-18       Impact factor: 3.630

Review 5.  Sibutramine on cardiovascular outcome.

Authors:  André J Scheen
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

6.  Sibutramine (reductil®)-induced cutaneous leukocytoclastic vasculitis: a case report.

Authors:  You Jin Ha; You Jin Han; You Won Choi; Ki Bum Myung; Hae Young Choi
Journal:  Ann Dermatol       Date:  2011-11-03       Impact factor: 1.444

Review 7.  Dietary Supplements as Source of Unintentional Doping.

Authors:  Vanya Rangelov Kozhuharov; Kalin Ivanov; Stanislava Ivanova
Journal:  Biomed Res Int       Date:  2022-04-22       Impact factor: 3.246

Review 8.  The risk of cardiovascular complications with current obesity drugs.

Authors:  Ariana M Chao; Thomas A Wadden; Robert I Berkowitz; Kerry Quigley; Frank Silvestry
Journal:  Expert Opin Drug Saf       Date:  2020-09-09       Impact factor: 4.250

9.  The role of psychobiological and neuroendocrine mechanisms in appetite regulation and obesity.

Authors:  Ioanna Paspala; Niki Katsiki; Dorothea Kapoukranidou; Dimitri P Mikhailidis; Anna Tsiligiroglou-Fachantidou
Journal:  Open Cardiovasc Med J       Date:  2012-12-28

Review 10.  Adverse Psychiatric Effects Associated with Herbal Weight-Loss Products.

Authors:  F Saverio Bersani; Marialuce Coviello; Claudio Imperatori; Marta Francesconi; Christina M Hough; Giuseppe Valeriani; Gianfranco De Stefano; Flaminia Bolzan Mariotti Posocco; Rita Santacroce; Amedeo Minichino; Ornella Corazza
Journal:  Biomed Res Int       Date:  2015-09-17       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.